Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Benedictuson Feb 05, 2019 10:51am
200 Views
Post# 29320383

RE:News: Bought deal for 20M shares at 0.25.

RE:News: Bought deal for 20M shares at 0.25. this is why its so frustrating to be in early stage companies like ate.v. So much promise and yet, so much dilution! I had thought the next raise (if needed) would be post the upcoming Q2 results and, therefore, far less dilutive than at current prices. Now I understand why the sp was languishing even prior to yesterday's PR despite the commencement of the clincial trial. Super frustrating to be a minnow in the land of shark financiers.  22 - 23 area should be strong support.  I continue to hold my position and hope that this is the last raise prior to stellar results and a partnership announcement.

Dec 2018 PR snippet: 

Dan Legault, CEO of Antibe, commented, “The exercising of these warrants shows continued confidence by our investors in Antibe’s drug development programs. Furthermore, the gross proceeds together with cash-on-hand fund the balance of our upcoming Phase 2B clinical trial for ATB-346, expected to start in Q1 2019 with results anticipated in Q2 2019.”

current PR snippet:

“This strategic financing will allow us to fund additional development activities for ATB-346 that set the stage for Phase 3 development and fulfill key requirements for regulatory progression and approval,” commented Dan Legault, CEO of Antibe. “This should strengthen our position as we advance global partnering discussions later this year in an effort to fully monetize ATB-346 for shareholders.”
Bullboard Posts